Zacks Research Predicts Amarin’s Q3 Earnings (NASDAQ:AMRN)

Amarin Corporation PLC (NASDAQ:AMRN) – Analysts at Zacks Research dropped their Q3 2026 earnings per share (EPS) estimates for Amarin in a research note issued to investors on Tuesday, June 16th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings of ($0.35) per share for the quarter, down from their previous forecast of ($0.32). Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Amarin’s current full-year earnings is ($1.15) per share. Zacks Research also issued estimates for Amarin’s Q4 2026 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.21) EPS, Q3 2027 earnings at ($0.25) EPS, Q4 2027 earnings at ($0.26) EPS, FY2027 earnings at ($0.88) EPS, Q1 2028 earnings at ($0.15) EPS and FY2028 earnings at ($0.70) EPS.

AMRN has been the topic of a number of other reports. Wall Street Zen lowered shares of Amarin from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amarin in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $12.00.

Amarin Trading Up 4.0%

Shares of AMRN stock opened at $15.77 on Thursday. The firm has a market capitalization of $330.70 million, a PE ratio of -24.26 and a beta of 0.82. The firm has a fifty day simple moving average of $14.60 and a two-hundred day simple moving average of $14.74. Amarin has a 12 month low of $12.30 and a 12 month high of $20.90.

Institutional Investors Weigh In On Amarin

Institutional investors and hedge funds have recently bought and sold shares of the stock. Banque Cantonale Vaudoise bought a new position in Amarin during the 3rd quarter valued at $32,000. Headlands Technologies LLC purchased a new stake in shares of Amarin in the second quarter valued at about $44,000. Brooklands Fund Management Ltd purchased a new stake in shares of Amarin in the fourth quarter valued at about $42,000. Northwestern Mutual Wealth Management Co. lifted its position in shares of Amarin by 1,816.7% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 5,750 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 5,450 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in Amarin by 56.8% during the fourth quarter. New York State Common Retirement Fund now owns 7,605 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 2,756 shares during the last quarter. 22.25% of the stock is owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.